Spark Biomedical develops wearable neurostimulation devices for bioelectronic medicine, targeting behavioral health, women’s health, hemostasis, pediatrics, and chronic pain. The company brings new wearable neurostimulation treatment options to market and aims to empower healthcare providers and researchers with tools for complex care situations. Led by CEO Daniel Powell, Spark Biomedical focuses on translating bioelectronic approaches into clinical-grade medical devices. The company plans to use new funding to accelerate development of its bioelectronic treatments and expand its core areas of business. No operating metrics were disclosed in the article. Five Liters is a Dallas-based subsidiary of Spark Biomedical developing non-invasive, wearable transcutaneous auricular neurostimulation (tAN) to explore hemostatic effects of vagus nerve stimulation (VNS) and reduce blood loss. The company is preparing a series of first-in-human studies in collaboration with Northwell Health’s Feinstein Institutes for Medical Research. Initial clinical trials will prioritize von Willebrand Disease (VWD) and aim to prevent life-threatening bleeding associated with inheritable bleeding disorders, surgical blood loss, and traumatic bleeding. Five Liters positions its technology as a non-pharmacological, wearable option for managing excessive blood loss. The company leverages its parent Spark Biomedical’s experience in tAN devices; Spark Biomedical also markets the FDA-cleared Sparrow Ascent system for opioid withdrawal. Financially, Five Liters announced a $500,000 investment from Pathway to Cures to support its early-stage research and clinical work.

Total raised

$16M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2025